Insufficient Growth At Oryzon Genomics S.A. (BME:ORY) Hampers Share Price

You may think that with a price-to-sales (or "P/S") ratio of 6.8x Oryzon Genomics S.A. (BME:ORY) is a stock worth checking out, seeing as almost half of all the Biotechs companies in Spain have P/S ratios greater than 8.6x and even P/S higher than 27x aren't out of the ordinary. However, the P/S might be low for a reason and it requires further investigation to determine if it's justified.

See our latest analysis for Oryzon Genomics

How Oryzon Genomics Has Been Performing

Oryzon Genomics hasn't been tracking well recently as its declining revenue compares poorly to other companies, which have seen some growth in their revenues on average. The P/S ratio is probably low because investors think this poor revenue performance isn't going to get any better. If you still like the company, you'd be hoping this isn't the case so that you could potentially pick up some stock while it's out of favour.

If you'd like to see what analysts are forecasting going forward, you should check out our free report on Oryzon Genomics.

Is There Any Revenue Growth Forecasted For Oryzon Genomics?

In order to justify its P/S ratio, Oryzon Genomics would need to produce sluggish growth that's trailing the industry.

Retrospectively, the last year delivered a frustrating 4.7% decrease to the company's top line. Still, the latest three year period has seen an excellent 43% overall rise in revenue, in spite of its unsatisfying short-term performance. Although it's been a bumpy ride, it's still fair to say the revenue growth recently has been more than adequate for the company.

Turning to the outlook, the next three years should generate growth of 51% each year as estimated by the four analysts watching the company. Meanwhile, the rest of the industry is forecast to expand by 64% each year, which is noticeably more attractive.

With this in consideration, its clear as to why Oryzon Genomics' P/S is falling short industry peers. It seems most investors are expecting to see limited future growth and are only willing to pay a reduced amount for the stock.

The Bottom Line On Oryzon Genomics' P/S

Typically, we'd caution against reading too much into price-to-sales ratios when settling on investment decisions, though it can reveal plenty about what other market participants think about the company.

As expected, our analysis of Oryzon Genomics' analyst forecasts confirms that the company's underwhelming revenue outlook is a major contributor to its low P/S. Right now shareholders are accepting the low P/S as they concede future revenue probably won't provide any pleasant surprises. It's hard to see the share price rising strongly in the near future under these circumstances.

Before you take the next step, you should know about the 2 warning signs for Oryzon Genomics (1 is concerning!) that we have uncovered.

If companies with solid past earnings growth is up your alley, you may wish to see this free collection of other companies with strong earnings growth and low P/E ratios.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.